GO
Loading...

Pharmaceuticals

More

  • *FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...

  • March 6- Lower-cost versions of biological drugs, known as biosimilars, are taking aim at some of the world's biggest-selling medicines. Unlike chemical compounds, such as aspirin or statins, these biotech products are made of hormones, antibodies and other proteins. DIFFERENT REGULATORY PATHWAYS Biosimilars are already sold in Europe, Japan and other parts...

  • Did Abbie overpay for Pharmacyclics?  Thursday, 5 Mar 2015 | 7:47 PM ET

    Raghuram Selvaraju, managing director, Healthcare equity research at MLV & Co, discusses whether AbbVie's acquisition of Pharmacyclics for about $21 billion is a good move.

  • How will Pharmacyclics complement AbbVie?  Thursday, 5 Mar 2015 | 5:23 PM ET

    Sachin Shah, merger arbitrage strategist at Albert Fried and Company, discusses why AbbVie's decision to buy Pharmacyclics for about $21 billion is a "longer-dated" move.

  • Is Wall Street losing out to European stocks?  Thursday, 5 Mar 2015 | 5:09 PM ET

    Joe Bell, senior equity strategist at Schaeffer's Investment Research, explains why ongoing capital fund flows into Europe could be positive for Wall Street on a "relative basis."

  • *Analysts view deal as strategic fit for Mallinckrodt. March 5- Dublin- based drugmaker Mallinckrodt Plc strengthened its presence in U.S. hospitals as it agreed to buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion. Shares of Mallinckrodt, a seller of generics, specialty drugs and medical imaging agents, jumped as...

  • AbbVie buying Pharmacyclics for $21B  Thursday, 5 Mar 2015 | 11:48 AM ET

    CNBC's Meg Tirrell has details on the biotech deal between AbbVie and Pharmacyclics.

  • LONDON, March 5- AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. AbbVie's planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector...

  • March 5- Mallinckrodt Plc said it would buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion to expand its reach in hospitals. Shares of Mallinckrodt, a seller of generics, specialty drugs and medical imaging agents, were up 5 percent at $122 in premarket trading. Mallinckrodt expects the acquisition to add at least...

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • AbbVie will spend about $21 billion to buy fellow drugmaker Pharmacyclics and add another major revenue producer to a portfolio that already includes the world's top-selling drug. AbbVie executives told analysts on Thursday that their company could reap more than $7 million in annual sales from Imbruvica in a few years. While AbbVie touted the potential...

  • AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday on the Nasdaq. Pharmacyclics stockholders can elect cash, AbbVie stock or a combination, subject to proration, the company said in a statement. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated...

  • AbbVie to buy Pharmacyclics in $21 billion deal Wednesday, 4 Mar 2015 | 10:59 PM ET

    March 4- AbbVie Inc said it will buy cancer drug company Pharmacyclics Inc in a $21 billion deal.

  • Nikkei edges up, BOJ's ETF buying helps sentiment Wednesday, 4 Mar 2015 | 9:28 PM ET

    *Rakuten falls after Goldman cuts rating. TOKYO, March 5- Japan's Nikkei share average edged up on Thursday after the central bank bought more exchange-traded funds, but gains were limited by investor caution ahead of U.S. jobs data on Friday. Ono Pharmaceutical Co, which co-develops cancer treatment drug Opdivo with Bristol Myers Squibb, jumped 8 percent after...

  • March 4- Johnson& Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources. A bid from J&J is expected to value Pharmacyclics near its $17.5 billion market value or at a premium, FT said on Wednesday, citing people familiar with the matter. Bloomberg reported last month, citing sources, that...

  • Technology is raising a high bar for high-end mixology Wednesday, 4 Mar 2015 | 1:42 PM ET

    Take the "Highlander," a cocktail offered at Barmini in Washington, D.C. The drink is a combination of bartender Juan Coronado's favorite highland ingredients, scotch and mezcal from Oaxaca, combined with a touch of simple syrup and served in a glass with a floating cloud of creme de cocoa, rosemary, citrus peels and dry ice. "It's quite amazing to see this floating...

  • *Actavis launches $21 billion bond deal. *Exxon Mobil to sell $7 billion in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record, according to Thomson Reuters unit IFR.

  • TORONTO, March 3- Canada's stock market regulator said on Tuesday it will amend or cancel trades in the shares of tiny pharmaceutical company Immunovaccine Inc after they surged on Friday following a hoax. The stock jumped more than 30 percent to 89 Canadian cents after an unauthorized statement said Immunovaccine had entered a partnership with a much larger...

  • FDA warning: men's testosterone drugs overused Tuesday, 3 Mar 2015 | 12:10 PM ET

    Additionally, the FDA cautioned that the drugs may increase the risk of heart attack, stroke and other cardiovascular problems. Drugmakers must add information about that potential risk to their prescribing labels and conduct a long-term study to further examine the issue, the FDA said. The FDA action follows years of industry marketing for new gels, patches...

  • *Actavis launches $21 bln bond deal. *Exxon Mobil to sell $7 bln in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record according to Thomson Reuters unit IFR.